Media Articles Related to Xolair (Omalizumab)
NICE gives the go ahead for the use of Xolair® (omalizumab) to treat potentially disabling skin condition
Source: Dermatology News From Medical News Today [2015.03.11]
Novartis is delighted that the National Institute of Health and Care Excellence (NICE) has recommended Xolair® (omalizumab) as an option for add-on therapy for treating severe CSU for adults...
Xolair® improves rate of severe asthma exacerbations
Source: Doctors Lounge - Chest Diseases
Xolair reduced the rate of hospital emergency visits by 44% in patients with inadequately controlled asthma.
FDA Panel Backs Breo Ellipta for Asthma in Adults
Source: Medscape Medical News Headlines [2015.03.20]
The panel recommended against approving the long-acting beta-agonist combination therapy for children, primarily due to safety concerns.
Medscape Medical News
Study uncovers new clues about overproduction of mucus in asthma and COPD
Source: Respiratory / Asthma News From Medical News Today [2015.03.19]
New insights into how mucus is overproduced in diseases like asthma and COPD may lead to new treatments for these and other airway diseases.
FDA Staff Finds No New Safety Problems With Glaxo's Asthma Drug
Source: Medscape Allergy & Clinical Immunology Headlines [2015.03.18]
GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found.
Reuters Health Information
Published Studies Related to Xolair (Omalizumab)
Immunologic effects of omalizumab in children with severe refractory atopic
dermatitis: a randomized, placebo-controlled clinical trial. 
mediated by the TSLP pathway in young patients with severe refractory AD... CONCLUSIONS: Anti-IgE therapy with omalizumab decreases levels of cytokines that
Population-based efficacy modeling of omalizumab in patients with severe allergic
asthma inadequately controlled with standard therapy. 
Omalizumab, a recombinant humanized monoclonal antibody, is the first approved
anti-immunoglobulin E (IgE) agent for the treatment of subjects with moderate to
severe persistent allergic asthma that are inadequately controlled by the
standard of care... In addition, the resulting population models could be used to predict
population FEV1 or FeNO response for omalizumab and/or other anti-IgE
therapeutics for which PK-IgE models are constructed.
Omalizumab is effective in allergic and nonallergic patients with nasal polyps
and asthma. 
omalizumab in patients with nasal polyps and comorbid asthma... CONCLUSION: Omalizumab demonstrated clinical efficacy in the treatment of nasal
Omalizumab and the risk of malignancy: results from a pooled analysis. 
pooled data from clinical trials of omalizumab-treated patients... CONCLUSIONS: In this pooled analysis no association was observed between
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. [2011.09]
BACKGROUND: Proof-of-concept studies with omalizumab in patients with chronic idiopathic urticaria (CIU) have shown significant decreases in mean urticaria activity scores (UASs). OBJECTIVE: We sought to evaluate the efficacy and safety of omalizumab in patients with CIU who remain symptomatic despite concomitant H(1)-antihistamine therapy... CONCLUSION: This study demonstrated that a fixed dose of 300 or 600 mg of omalizumab provides rapid and effective treatment of CIU in patients who are symptomatic despite treatment with H(1)-antihistamines. Copyright (c) 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Clinical Trials Related to Xolair (Omalizumab)
Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids [Completed]
In patients with at least moderate persistent allergic asthma controlled with inhaled
steroids, omalizumab (administered per US product label), when compared to placebo, will
provide the participants with significantly improved tolerability of specific allergen
immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).
The Effect of Xolair (Omalizumab) on Allergy Blood Cells [Recruiting]
We are studying Xolair (omalizumab) to see it's effect on allergic blood cells. The blood
tests will be done in a test tube to see if they react differently before and after
treatment. The blood cells will be mixed with to whatever the person is allergic.
Effect of Xolair on Airway Hyperresponsiveness [Recruiting]
The purpose of this study is to determine if Xolair can reduce the abnormal increase in
limitation to airflow in patients with asthma in a relatively short time period. Another
purpose is to determine if Xolair will decrease the amount of inflammation in the lungs of
an asthmatic patient in the same time period.
Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab [Terminated]
Ozone can cause acute airway inflammation in both asthmatics and normal volunteers. However,
in asthmatics ozone can cause episodes of worsening of asthma. We want to learn if chronic
allergic response, known as "IgE-induced airway inflammation" is what causes the increased
inflammation in response to ozone. To do this we will examine the response to ozone in a
group of asthmatics treated with omalizumab, a medicine available and approved for use in
people with asthma, or a placebo control. The placebo for this study is inert physiologic
saline ("salt water") which contains no omalizumab. Both the omalizumab and the placebo will
be administered as an injection under the skin. Omalizumab, also called Xolair, is a
humanized monoclonal antibody, which means that it originally was produced in mice, then
genetically engineered to look more like human than mouse antibody. Omalizumab inactivates
IgE, a protein our own immune systems make as part of allergic reactions. The purpose of this
study is to test the hypothesis that omalizumab, by blocking this aspect of allergic
reactions, will decrease the number of inflammatory cells in the airway after ozone
challenge. We also hypothesize that omalizumab will decrease the effects of ozone on changes
in lung function, mucociliary clearance (a measure of how quickly mucus clears form the
airway) and airway reactivity. Airway reactivity is a measure of how sensitive the airways
are to a medication used to diagnose asthma, called methacholine. We will examine these as
additional information we can learn during the course of the study. This is a blinded study,
meaning that neither you nor the researchers know if you get the active drug or placebo, but
that information can be obtained if needed. The placebo is an injection of inert
physiological saline ("salt water") which contains no omalizumab.
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair [Recruiting]
The purpose of this study is to study the effects of Xolair using non-invasive techniques
from the expired gas of patients with moderate to severe allergic asthma.
Reports of Suspected Xolair (Omalizumab) Side Effects
Blood Pressure Increased (178),
Headache (169), more >>